2nd Floor Lia B/D
11 articles with KAEL–GemVax
Samsung Pharm & GemVax present pancreatic cancer immunotherapeutic drug, RIAVAX™, phase III results at ASCO 2021
Samsung Pharm Co., Ltd. announced that the company presented the results of a phase III clinical trial of its pancreatic cancer immunotherapeutic drug candidate called 'RIAVAX™ ' conducted in Korea at the 2021 American Society of Clinical Oncology Annual meeting.
GemVax's highly promising Phase II Alzheimer's disease clinical trial results targeting telomerase published in prestigious Alzheimer's Research & Therapy' journal
GemVax & KAEL Co., Ltd. has announced that a paper on GV1001, a novel Alzheimer's treatment based on telomerase modification, was published on March 26th in the SCI-grade international journal 'Alzheimer's Research & Therapy'.
10/8/2020Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Promising Phase II results underpin GemVax decision to apply for expanded access IND for GV1001 in Alzheimer's Disease
GemVax & KAEL a clinical stage company developing novel immunotherapies based on telomerase modification announced the decision to apply for an expanded access IND for its lead candidate GV1001 to include additional investigational groups in Alzheimer's, a disease the WHO estimates to affect 24 million people worldwide, in its clinical development program.
The 12th Clinical Trials on Alzheimer's Disease 2019 was held in San Diego, USA, from December 4-7. At the CTAD, the results of various Alzheimer's disease clinical trials were shared, and it provided a glimpse into the possibility of treating Alzheimer's disease.
KAEL–GemVax Release: Final Results From the Phase III TeloVac Trial in Pancreatic Cancer Presented at American Society of Clinical Oncology, Chicago, June 3rd 2013.
KAEL–GemVax Reports Encouraging Interim Progress in Phase II Study of GV1001 Anti-telomerase Vaccine in NSCLC
Lytix Biopharma and KAEL–GemVax Announce First Patient Treated in Clinical Trial to Combine LTX-315 and GV1001 Cancer Vaccine Immunotherapy
KAEL–GemVax Reports Significant Interim Progress In UK Telovac Phase III Study Of GV1001 Anti-Telomerase Vaccine In Pancreatic Cancer
Lytix Biopharma and KAEL–GemVax announce approval of joint clinical trial to combine LTX-315 and GV1001 cancer vaccine immunotherapy